Reference : //caonline.amcancersoc.org/cgi/content/abstract/29/2/84

John C. Ruckdeschel M.D.1, Richard Caradonna M.D., William J. Paladine M.D., Stephen M. Hillinger M.D.2, and John Horton M.B., Ch.B.3
1. Assistant Professor of Medicine in Oncology, Albany Medical College, Albany, New York, Medical Director, Cancer Treatment Center, St. Mary's Hospital, Troy, New York, and American Cancer Society Junior Faculty Clinical Fellow.

2. Assistant Professor of Medicine in Oncology, Albany Medical College, Albany, New York, and American Cancer Society Junior Faculty Clinical Fellow.

3. Professor of Medicine and Head, Division of Oncology, Albany Medical College, Albany, New York.

Small cell carcinoma of the lung has joined the ranks of cancers that are increasingly susceptible to successful therapeutic attack. Cautious optimism about potential cures is being expressed in a disease that a few short years ago had a median survival of two months. Advances in cell biology, particularly in the area of metastases, are leading to new concepts in therapy, but more than ever there is a crying need for controlled studies of new approaches.